BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

KLP Kapitalforvaltning AS bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the fourth quarter, ...

Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and $50 price target Therapeutic options for patients with transthyretin ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

BridgeBio Pharma said Finance Chief Brian Stephenson is leaving the company for personal reasons and will be replaced by Thomas Trimarch, who will continue holding the president role.

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.